nach oben

Tipp

Radiofrequency ablation of Barrett’s esophagus and early cancer within the background of the pathophysiology of the disease

verfasst von: I. Mesteri, L. Beller, S. Fischer-See, S. Schoppmann, J. Lenglinger, F. Wrba, M. Riegler, J. Zacherl

Erschienen in: European Surgery | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Summary

Background

Barrett’s esophagus (BE) is the morphological consequence of gastroesophageal reflux disease (GERD). Via low- and high-grade dysplasia, nondysplastic Barrett’s esophagus (NDBE) may progress to cancer (0.1–0.6 % annual risk). We aim to summarize the impact of radiofrequency ablation (RFA) for the elimination of BE and cancer prevention.

Methods

This PUB MED search included 136 papers on the pathophysiology, diagnosis, and therapy (RFA, antireflux surgery) of BE £ T1a.

Results

The reflux of gastric acid and bile mediate a complex neurohumoral response within the esophageal mucosa, which orchestrates the formation of NDBE, dysplasia, and cancer. RFA effectively eliminates NDBE, dysplasia, and flat T1a cancer. Following 1–6 treatment sessions and 1–3.5 years follow-up, RFA for dysplastic BE effectively eliminates dysplasia and NDBE in > 80 and > 60 % of the cases, respectively, and mediates the development of a mucosa without genetic abnormalities. After 1–3 treatments for NDBE and 5 years follow-up, RFA eradicates NDBE in 92 % of the cases. NDBE expresses the genetic abnormalities of dysplasia and cancer and shares the same cancer risk as colonic polyps. Therefore, within clinical trials, RFA for NDBE should be offered to persons with NDBE and a risk profile, which predisposes them for cancer development (family history, GERD > 10 years, etc.). Antireflux surgery increases the yield of RFA for NDBE.

Conclusions

RFA (± endoscopic resection) is recommended for the elimination of BE with dysplasia and early cancer (T1a). Larger tumors are treated by surgical resection. The biological and genetic properties of NDBE justify the examination of RFA for this indication within clinical trials. Future studies will have to elucidate the combination of RFA, antireflux surgery, and medical therapy (PPI, statins, nonsteroidal antiinflammatory drugs) for cancer prevention.

Vorheriger Artikel Rare oesophageal tumours: experience of one centre

Nächster Artikel The early results of intragastric balloon application of different BMI groups

Becher A, Dent J. Systematic review: ageing and gastro-oesophageal reflux disease symptoms, esophageal function and reflux oesophagitis. Aliment Pharmacol Ther. 2011;33(4):442–54. PubMed

Kamolz T, Velanovich V. The impact of disease and treatment on health-related quality of life in patients suffering from GERD. In: Granderath FA, Kamolz T, Pointner R, editors. Gastroesophageal reflux disease, principles of disease, diagnosis and treatment. New York: Springer Wien; 2006. pp. 287–98.

Chandrasoma PT. Columnar lined esophagus: what it is and what it tells us. Eur Surg. 2006;38/3:197–209.

Lenglinger J, Eisler M, Wrba F, et al. Update: histopathology-based definition of gastroesophageal reflux disease and Barrett’s esophagus. Eur Surg. 2008;40/4:165–75.

Lenglinger J, Izay B, Eisler M, et al. Barrett’s esophagus: size of the problem and diagnostic value of a novel histopathology classification. Eur Surg. 2009;41/1:26–39.

Goldblum JR. Controversies in the diagnosis of Barrett esophagus ad Barrett-related dysplasia. Arch Pathol Lab Med. 2010;134:1479–84. PubMed

Odze RD. What the gastroenterologist needs to know about the histology of Barrett’s esophagus. Curr Opin Gastroenterol. 2011 27(4):389–96. PubMed

Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol. 2012 Jan;36(1):1–7. PubMed

Hvid-Jensen F, Pedersen L, Mohr Drewes A, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–83. PubMed

10.

Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012 Jul;61(7):970–6. PubMed

11.

De Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett’s oesophagus: Dutch nationwide cohort study. Gut. 2010;59(8):1030–6. PubMed

12.

Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–72. PubMed

13.

Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systemic review. Am J Gastroenterol. 2009;104:502–13. PubMed

14.

Kastelein F, Spaander MCW, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventive effects in patients with Barrett’s esophagus. Gastroenterology. 2011 Dec;141(6):2000–8. PubMed

15.

Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low grade dysplastic Barrett’s esophagus. Dig Dis Sci. 2010;55:1918–31. PubMed

16.

Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanism, and endoscopic treatment of Barrett’s esophagus. Gastroenterology. 2010;138(3):854–69. PubMed

17.

Spechler SJ. Screening and surveillance for Barrett’s esophagus—an unresolved dilemma. Nat Clin Pract Gastroenterol & Hepatol. 2007;4(9):470–1.

18.

Manner H, May A, Pech O, et al. Early Barrett’s carcinoma with “low risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103:2589–97. PubMed

19.

Zehetner J, DeMeester SR, Hagen JA, et al. Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141:39–47. PubMed

20.

Gordon LG, Eckermann S, Hirst NG, et al. Healthcare resource use and medical cost for the management of oesophageal cancer. Br J Surg. 2011;98(11):1589–98. PubMed

21.

Triadafilopoulos G. Proton pump inhibitor in Barrett’s esophagus: pluripotent but controversial. Eur Surg. 2008;40/2:58–65.

22.

Chandrasoma P, Wijetunge S, Ma Y, DeMeester S, et al. The dilated distal esophagus: a new entity that is the pathologic basis of early gastroesophageal reflux disease. Am J Surg Pathol. 2011;35(12):1873–81. PubMed

23.

Chandrasoma P, Wijetunge S, DeMeester SR, et al. The histologic squamo-oxyntic gap: an accurate and reproducible diagnostic marker of gastroesophageal reflux disease. Am J Surg Pathol. 2010;34(11):1574–81. PubMed

24.

Glickman JN, Spechler SJ, Souza RF, et al. Multilayered epithelium in mucosal biopsy specimens from the gastroesphageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol. 2009;33:818–25. PubMed

25.

Öberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg. 1997;226(4):522–32. PubMed

26.

Singh R, Yi SLC, Sethi S. Advanced endoscopic imaging in Barrett’s esophagus: a review on current practice. World J Gastroenterol. 2011;17(38):4271–6. PubMed

27.

Coco DP, Goldblum JR, Hornick JL, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol. 2011;35:45–54. PubMed

28.

Bennett AE, Goldblum JR, Odze R. Inflammatory disorders of the esophagus. In: Odze R, Goldblum JR, editors. Surgical pathology of the GI tract, liver, biliary tract, an pancreas. 2nd ed. Philadelphia: Saunders Elsevier; 2009. pp. 256–64.

29.

Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95(4):260–9. PubMed

30.

Schoppmann SF, Prager G, Langer FB, et al. Open versus minimally invasive esophagectomy: a single-center case controlled study. Surg Endosc. 2010;24(12):3044–53. PubMed

31.

Curvers WL, ten Kate FJ, Krishnadad KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30. PubMed

32.

Ringhofer C, Lenglinger J, Izay B, et al. Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr. 2008;120/11:350–9.

33.

Mueller J, Werner M, Stolte M. Barrett’s esophagus: histopathologic definitions and diagnostic criteria. World J Surg. 2004;28(2):148–54. PubMed

34.

Müller M, Gockel I, Hedwig P, et al. Is the Schatzki ring a unique esophageal entity? World J Gastroenterol. 2011;17(23):2838–43.

35.

Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M ctriteria. Gastroenterology. 2006;131(5):1392–9. PubMed

36.

Oezcelik A, DeMeester SR. General anatomy of the esophagus. Thorac Surg Clin. 2011;21(2):289–97. PubMed

37.

Ayazi S, Tanhankar A, DeMeester SR, et al. The impact of gastric distension on the lower esophageal sphincter and its exposure to acid gastric juice. Ann Surg. 2010;252:57–62. PubMed

38.

Bredenoord AJ. High-resolution manometry—bliss upon bliss for the esophagology? Eur Surg. 2007;39/3:176–3.

39.

Savarino E, Gemignani L, Pohl D, et al. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34(4):476–86. PubMed

40.

Atasoy S, Mateus D, Meining A, et al. Targeted optical biopsies for surveillance endoscopies. Med Image Comput Assist Interv. 2011;14(3):83–90.

41.

Wijetunge S, Ma Y, DeMeester S, et al. Association of adenocarcinoma of the distal esophagus, “gastroesophageal junction”, and “gastric cardia” with gastric pathology. Am J Surg Pathol. 2010;34(10):1521–7. PubMed

42.

Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care—the ProGERD study. Aliment Pharmacol Ther. 2012;35(1):154–64. PubMed

43.

Oh SD, DeMeester SR. Pathophysiology and treatment of Barrett’s esophagus. World J Surg. 2010;16(30):3762–72.

44.

Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–7. PubMed

45.

Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461–7. PubMed

46.

Ronkainen J, Aro P, Storskrubb, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopy study. Gastroenterology. 2005;129:1825–31.

47.

Hayeck TJ, Kong CY, Spechler SJ, et al. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esoph. 2010;23(6):451–7.

48.

Thrift AP, Pandeya N, Smith KJ, et al. Helicobacter pylori infection and the risks of Barrett’s oesophagus: a population-based case-control study. Int J Cancer. 2012 May 15;130(10):2407–16. PubMed

49.

Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–88. PubMed

50.

Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol. 2010;298:G571–81.

51.

Goldman A, Chen HD, Roesly HB, et al. Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett’s esophagus pathogenesis. Am J Physiol. 2010;300:G292–302.

52.

Huo X, Juergens S, Zhang X, et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kB activation in benign Barrett’s epithelialc ells. Am J Physiol. 2011;301:G278–86.

53.

Zhang HY, Hormi Carver K, Zhang X, et al. In benign Barrett’s epithelial cells, acid exposure generates reactive oxygen species that cause DNA double strand breaks. Cancer Res. 2009;69:9083–9. PubMed

54.

Zhang HY, Zhang Q, Zhang X, et al. Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells. Am J Physiol. 2011;300:G454–60.

55.

Tobey NA, Hosseini SS, Argote CM, et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2004;99(1):13–22. PubMed

56.

Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005;128(3):771–8. PubMed

57.

Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137:1776–84. PubMed

58.

Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esoph. 2008;21:43–50.

59.

Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett’s-like metaplasia. Cell. 2011;145:1023–35. PubMed

60.

Bobryshev YV, Freeman AK, Botelho NK, et al. Expression of the putative stem cell marker Musashi-1 in Barrett’s esophagus and esophageal adenocarcinoma. Dis Esoph. 2010;23:580–9.

61.

Souza RF, Schwartz RE, Mashimo H. Esophageal stem cells and 3D-cell culture models. Ann NY Acad Sci. 2011;1232:316–22. PubMed

62.

Vega KJ, May R, Sureban SM, et al. Identification of the putative intestinal stem cell marker DCAMKL-1 in Barrett’s esophagus and esophageal adenocarcinoma. J Gastroenterol Hepatol. 2012 Apr;27(4):773–80. PubMed

63.

Milano F, van Baal JW, Buttar NS, et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology. 2007;132:2412–21. PubMed

64.

Castillo D, Puig S, Iglesias M, et al. Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett’s esophagus. J Gastroinest Surg. 2012 Feb;16(2):227–37.

65.

Huo X, Zhang HY, Zhang X, et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett’s esophagus. Gastroenterology. 2010;139:194–203. PubMed

66.

Hayes S, Ahmed S, Clark P. Immunohistochemical assessment for CDx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence. J Clin Pathol. 2011;64:110–3. PubMed

67.

McIntire MG, Soucy G, Vaughan TL, et al. MUC2 is a highly specific marker of goblet cell metaplasia in the distal esophagus and the gastroesophageal junction. Am J Surg Pathol. 2011;35:1007–13. PubMed

68.

Yamanaka Y, Shiotani A, Fujimura Y, et al. Expression of sonic hedgehog (SHH) and CDX2 in the columnar epithelium of the lower esophagus. Dig Liv Dis. 2011;43:54–9.

69.

DeMeester SR. Reflux, Barrett’s and adenocarcinoma of the esophagus: can we disrupt the pathway? J Gastrointest Surg. 2010;14:941–54. PubMed

70.

Riegler M. Barrett’s esophagus: filling the gap. Eur Surg. 2010;42/1:1–3.

71.

Heijmans J, Van Den Brink GR. Morphogens and the parietal cell: shaping up acid secretion. Gastroenterology. 2010;139(6):1830–3. PubMed

72.

Kazumori H, Ishihara S, Takahashi Y, et al. Roles of Krüppel-like factor 4 in oesophageal epithelial cells in Barrett’s espithelium development. Gut. 2011;60:608–17. PubMed

73.

Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest. 1996;98:2120–8. PubMed

74.

Goldman A, Shahidullah M, Goldman D, et al. A novel mechanism of acid and bile-induced DNA damage involving Na+/H+ exchanger: implication for Barrett’s esophagus. Gut. 2010 Dec;59(12):1606–16. PubMed

75.

Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett’s esophagus. Cancer Lett. 2009;275:170–7. PubMed

76.

Smith E, Kelly JJ, Ruskiewicz AR, et al. The effect of long-term control of reflux by fundoplication on aberrant deoxyribonucleic acid methylation in patients with Barrett’s esophagus. Ann Surg. 2010;252:63–9. PubMed

77.

Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroetnerol. 2009;104(4):816–24.

78.

Hahn HP, Blount PL, Ayub K, et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol. 2009;33(7):1006–15. PubMed

79.

Theodorou D, Ayazi S, DeMeester SR, et al. Intraluminal pH and goblet cell density in Barrett’s esophagus. J Gastrointest Surg. 2012 Mar;16(3):469–74. PubMed

80.

Theisen J, Stein HJ, Feith M, et al. Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia. Surg Endosc. 2006;20(2):235–8. PubMed

81.

Öberg S, Johansson J, Wenner J, Walther B. Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Ann Surg. 2002;235(3):338–45. PubMed

82.

Dresner SM, Griffin SM, Bennett MK, et al. Human model of duodenogastro-oesophageal reflux in the development of Barrett’s metaplasia. Br J Surg. 2003;90:1120–8. PubMed

83.

Franchimont D, Covas A, Brasseur C, et al. Newly developed Barrett’s esophagus after subtotal esophagectomy. Endoscopy. 2003;35(10):850–3. PubMed

84.

Lord RVN, Wickramasinghe K, Johansson JJ, et al. Cardiac mucosa in the remnant esophagus after esophagectomy is an acquired epithelium with Barrett’s-like features. Surgery. 2004;136:633–40. PubMed

85.

Peitz U, Vieth M, Pross M, et al. Cardia-type metaplasia arising in the remnant esophagus after cardia resection. Gastrointest Endosc. 2004;59:810–7. PubMed

86.

Peitz U, Vieth M, Ebert M, et al. Small-bowel metaplasia arising in the remnant esophagus after esophagogastrostomy—a retrospective study in patients with a history of total gastrectomy. Am J Gastroenterol. 2005;100:2062–70. PubMed

87.

Saadi A, Shannon NB, Lao-Sirieix, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 2010;107(5):2177–82.

88.

Arora G, Basra S, Roorda AK, Triadafilopoulos G. Radiofrequency ablation for Barrett’s esophagus. Eur Surg. 2009;41/1:19–25.

89.

Moayyedi P, Burch N, Akhtar-danesh N, et al. Mortality rates in patients with Barrett’s esophagus. Aliment Pharmacol Ther. 2008;27:316–20. PubMed

90.

Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett’s oesophagus: results from a population based study. Gut. 2003;52:1081–4. PubMed

91.

Pouw RE, Sharma VK, Bergman JJ, Fleischer DE. Radiofrequency ablation for total Barrett’s eradication: a description of the endoscopic technique, its clinical results and future prospects. Endoscopy. 2008;40:1033–40. PubMed

92.

Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow up. Gastrointest Endosc. 2008;68(5):867–76. PubMed

93.

Lyday WD, Corbett FS, Kuperman DA, et al. Radiofrequency ablation of Barrett’s esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010;42:272–8. PubMed

94.

Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10):781–9. PubMed

95.

Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–8. PubMed

96.

Van Vilsteren FGI, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicenter randomized trial. Gut. 2011;60(6):765–73. PubMed

97.

Shaheen NJ, Peery AF, Hawes RH, et al. Quality of life following radiofrequency ablation of dysplastic Barrett’s esophagus. Endoscopy. 2010;42:790–9. PubMed

98.

Alvarez Herrero L, van Vilsteren FGI, Pouw RE, et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s esophagus longer than 10 cm. Gastrointest Endosc. 2011;73:682–90.

99.

Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc. 2008;68:35–40. PubMed

100.

Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136(7):2101–14. PubMed

101.

Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett’s esophagus: a systematic review. Am J Gastroenterol. 2011;106(11):1899–908. PubMed

102.

Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology. 2008;135(6):1899–1906. PubMed

103.

Merchea A, Cullinane DC, Sawyer MD, et al. Esophagogastroduodenoscopy-associated gastrointestinal perforations: a single center experience. Surgery. 2010;148(4):876–80. PubMed

104.

Kelty CJ, Cough MD, van Wyk Q, et al. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42:1271–4. PubMed

105.

Gatenby PAC, Ramus JR, CAygill CPJ, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43:524–30. PubMed

106.

El-Serag HB. Routine polypectomy for colorectal polyps and ablation for Barrett’s esophagus are intellectually the same. Gastroenterology. 2011;140:386–8. PubMed

107.

Horner MJ, et al. SEER cancer statistics review, 1975-2006, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2006, based on November 2008 SEER data submission, posted to the SEER web site. 2009.

108.

Abu-Sneineh A, Tam W, Schoeman M, et al. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett’s oesophagus. Aliment Pharm Ther. 2010;32:1023–30.

109.

Pouw RE, Gondrie JJ, Rygiel AM, et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am J Gastroenterol. 2009;104(6):1366–73. PubMed

110.

Beaumont H, Gondrie JJ, Pouw RE, et al. Stepwise radiofrequency ablation of Barrett’s esophagus preserves esophageal inner diameter, compliance, and motility. Endoscopy. 2009;41:2–8. PubMed

111.

Semlitsch T, Jeitler K, Schoefl R, et al. A systematic review of the evidence for radiofrequency ablation for Barrett’s esophagus. Surg Endosc. 2010;24(12):2935–43. PubMed

112.

Kahrilas P. The problems with surveillance of Barrett’s esophagus. N Engl J Med. 2010;365(15):1375–83.

113.

Sikkema M, Looman CWN, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106(7):1231–8. PubMed

114.

Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106(2):254–60. PubMed

115.

Wiseman EF, Ang YS. Risk factors for neoplastic progression in Barrett’s esophagus. World J Gastroenterol. 2011;17(32):3672–83. PubMed

116.

Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett’s esophagus by endoscopy indication. Gastrointest Endosc. 2010;71:21–7. PubMed

117.

Granderath FA, Kamolz T, Schweiger UM, et al. Long-term results of laparoscopic antireflux surgery. Surgical outcome and analysis of failure after 500 laparoscopic procedures. Surg Endosc. 2002;16:753–7. PubMed

118.

Wykypiel H, Wetscher GJ, Klingler P, Glaser K. The Nissen fundoplication: indication, technical aspects and postoperative outcome. Langenbecks Arch Surg. 2005;390:495–502. PubMed

119.

Vallböhmer D, DeMeester SR, Oh DS, et al. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol. 2006;101(7):1458–66. PubMed

120.

Koch OO, Kaindlsdorfer A, Antoniou SA, et al. Laparoscopic Nissen versus Toupet fundoplication: objective and subjective results of a prospective randomized trial. Surg Endosc. 2012 Feb;26(2):413–22. PubMed

121.

Mabrut JY, Baulieux J, Adham M, et al. Impact of antireflux operation on columnar lined esophagus. J Am Coll Surg. 2003;196(1):60–7. PubMed

122.

Gurski RR, Peters JH, Hagen JA, et al. Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg. 2003;196(5):706–12. PubMed

123.

Csendes A, Braghetto I, Burdiles P, et al. Late results of the surgical treatment of 125 patients with short-segment Barrett esophagus. Arch Surg. 2009;144(10):921–7. PubMed

124.

Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg. 2003;237(3):291–8. PubMed

125.

Rossi M, Barreca M, de Bartoli N, et al. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett’s esophagus. Ann Surg. 2006;243:58–63. PubMed

126.

Zaninotto G, Parente P, Salvador R, et al. Long-term follow-up of Barrett’s epithelium: medical versus antireflux surgical therapy. J Gastrointest Surg. 2012 Jan;16(1):7–14. PubMed

127.

Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg. 2007;246(1):11–21. PubMed

128.

Theisen J, Peters JH, Fein M, et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg. 2005;241:63–8. PubMed

129.

McQuaid KR, Laine L, Fennerty MB, et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34(2):146–65. PubMed

130.

Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng J Med. 1999;340(11):825–31.

131.

Lagergren J, Ye W, Lagegren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138(4):1297–301. PubMed

132.

Kauttu TME, Rantanen TK, Sihvo EI, et al. Esophageal adenocarcinoma arising after antireflux surgery: a population-based analysis. Eur J Cardiothor Surg. 2011;40:1450–4.

133.

Hubbard N, Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus in patients with fundoplication. Surg Endosc. 2007;21:625–8. PubMed

134.

dos Santos RS, Bizekis C, Ebright M, et al. Radiofrequency ablation fro Barrett’s esophagus and low grade dysplasia in combination with antireflux procedure: a new paradigm. J Thorac Cardiovasc Surg. 2010;139(3):713–6. PubMed

135.

O’Connell K, Velanovich V. Effects of Nissen fundplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2011;25(3):830–4. PubMed

136.

Goers TA, Leao P, Cassera MA, et al. Concomitant endoscopic radiofrequency ablation and laparoscopic reflux operative results in more effective and efficient treatment of Barrett’s esophagus. J Am Coll Surg. 2011;213(4):486–92. PubMed

137.

Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57. PubMed

Titel: Radiofrequency ablation of Barrett’s esophagus and early cancer within the background of the pathophysiology of the disease
verfasst von: I. Mesteri
L. Beller
S. Fischer-See
S. Schoppmann
J. Lenglinger
F. Wrba
M. Riegler
J. Zacherl
Publikationsdatum: 01.12.2012
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe 6/2012
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-012-0183-7

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Radiofrequency ablation of Barrett’s esophagus and early cancer within the background of the pathophysiology of the disease

Summary

Background

Methods

Results

Conclusions

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Surgical treatment of synchronous and metachronous hepatic–and pulmonary colorectal cancer metastases —the Copenhagen experience

The early results of intragastric balloon application of different BMI groups

Chillax surgery: back to the roots

Lymphangioma of the cervical esophagus associated with an inlet patch

Rare oesophageal tumours: experience of one centre

Parathyroid carcinoma in primary hyperparathyroidism: single institution experience